

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC and AMNEAL
PHARMACEUTICALS OF NEW YORK, LLC,
Petitioners,

v.

ALMIRALL, LLC
Patent Owner

Case IPR2019-00207
U.S. Pat. No. 9,517,219

PETITIONERS' EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

<i>Amneal Exhibit #</i>	<i>Description</i>
1001	U.S. Patent No. 9,517,219
1002	Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
1003	<i>Curriculum Vitae</i> for Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
1004	International Patent Application Publication No. WO 2009/061298 (“Garrett”)
1005	International Application Publication No. WO 2010/072958 (“Nadau-Fourcade”)
1006	Certification for Translation of WO 2010/072958
1007	U.S. Patent Publication No. 2006/0204526 (“Lathrop”)
1008	U.S. Patent Publication No. 2010/0029781 (“Morris”)
1009	Osborne, D.W., “Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products,” <i>J. Cosmetic Derm.</i> 10:324-329 (2011) (“Osborne I”)
1010	<i>Physician’s Desk Reference</i> , 65 th ed., pp. 599-602 (2011) (ACZONE Gel 5% Label)
1011	U.S. Patent No. 7,820,186 (“Orsoni”)
1012	Epiduo Product Label, approved December 8, 2008 (“Epiduo Label”)
1013	U.S. Patent Publication No. 2007/0190019 (“Guo”)
1014	Rowe, R.C. et al. (Eds.), <i>Handbook of Pharmaceutical Excipients</i> , 6th Ed., Pharmaceutical Press: London, UK (2009)
1015	Bonacucina, G., <i>et al.</i> , “Characterization and Stability of Emulsion Gels Based on Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer,” <i>AAPS PharmaSciTech</i> 10:368-375 (2009) (“Bonacucina”)
1016	U.S. Patent No. 5,863,560 (“Osborne II”)
1017	File History of U.S. Patent No. 9,517,219
1018	Declaration of Elaine S. Gilmore, M.D., Ph.D.

<i>Amneal Exhibit #</i>	<i>Description</i>
1019	<i>Curriculum Vitae</i> for Elaine S. Gilmore, M.D., Ph.D.
1020	Affidavit of Christopher Butler
1021	<i>Intentionally left blank</i>
1022	Wozel, D., "Innovative Use of Dapsone" <i>Dermatol. Clin.</i> 28: 599–610 (2010) ("Wozel")
1023	Thiboutot, D., <i>et al.</i> , "Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris" <i>Clin. Pharmacokinet.</i> 46: 697-712 (2007) ("Thiboutot")
1024	Nguyen, R. and Su, J., "Treatment of Acne Vulgaris" <i>Pediatrics and Child Health</i> 21: 119-125 (2010) ("Nguyen")
1025	Williams, H., <i>et al.</i> , "Acne vulgaris" <i>Lancet</i> 379: 361–72 (2012) ("Williams")
1026	Sepineo™ P 600 Brochure
1027	Barclay, L., "Use of Topical Corticosteroids for Dermatologic Conditions Reviewed" <i>Medscape</i> - Jan 21, 2009, accessed from https://www.medscape.com/viewarticle/587159_print ("Barclay")
1028	Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins: Baltimore, MD (2005) ("Remington")
1029	Kim, J-Y., <i>et al.</i> , "Rheological properties and microstructures of Carbopol gel network system," <i>Colloid. Polym. Sci.</i> 281:614–623(2003) ("Kim")
1030	<i>Intentionally left blank</i>
1031	Spain's Almirall bets on dermatology with \$650 million U.S. deal, Retrieved from https://www.reuters.com/article/us-allergan-m-a-almirall/spains-almirall-bets-on-dermatology-with-650-million-us-deal-idUSKBN1KO10N , last accessed October 26, 2018
1032	Piskin, S. <i>et al.</i> "A review of the use of adapalene for the treatment of acne vulgaris," <i>Therapeutics and Clinical Risk Management</i> 3(4): 621–624 (2007) ("Piskin")
1033	<i>Intentionally left blank</i>

<i>Amneal Exhibit #</i>	<i>Description</i>
1034	Andersson, D., "Evonik-Degussa expands its cooperation with Alsiano," <i>Pharma & Healthcare News</i> : 1-10 (2007)
1035	Poster Abstracts for the Journal of the American Academy of Dermatology 2017 Annual Meeting
1036	Email dated October 8, 2019 from Liz Hagan to Tyler Liu, Dennies Varughese, Adam LaRock and James Trainor regarding conference call
1037	Email dated October 8, 2019 from Tyler Liu to trials@uspto.gov requesting authorization to file a motion for additional discovery
1038	<i>Almirall, LLC v. Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals, Inc.</i> , Case 1:17-cv-00663 [Proposed] Joint Pretrial Order, Document 142, February 5, 2019

10252301_1.docx

Respectfully submitted,
 STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Date: October 18, 2019
 1100 New York Avenue, N.W.
 Washington, DC 20005-3934
 (202) 371-2600

Dennies Varughese, Pharm.D.
 Registration No. 61,868
 Attorney for Petitioners

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e), 42.105(a))


The undersigned hereby certifies that the above-captioned “Petitioners’ Exhibit List”, along with exhibits 1035 – 1038, were served in their entirety on October 18, 2019, via electronic mail upon the following counsel for Patent Owner:

James Trainor
Vanessa Park-Thompson
FENWICK & WEST LLP
902 Broadway, Suite 14
New York, NY 10010
Telephone (212) 430-2600
Facsimile (650)938-5200
jtrainor@fenwick.com
vpark-thompson@fenwick.com

Elizabeth B. Hagen
FENWICK & WEST LLP
1191 Second Avenue, 10th Floor
Seattle, WA 98101
Telephone (206) 389-4510
Facsimile (206)389-4511
ehagan@fenwick.com

Jennifer R. Bush
FENWICK & WEST LLP
801 California Street
Mountain View, CA 94041
Telephone (650) 988-8500
Facsimile (650) 938-5200
jbush@fenwich.com

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Date: October 18, 2019
1100 New York Avenue, N.W.
Washington, DC 20005-3934
(202) 371-2600

Dennies Varughese, Pharm.D.
Registration No. 61,868
Attorney for Petitioners